Table 3.
COVID-19 VE* against SARS-CoV-2 variant infection.
| COVID-19 Vaccines | Dose | VE % (95% CI) against SARS-CoV-2 Variant Documented Infection | ||||
|---|---|---|---|---|---|---|
| Alpha | Beta | Gamma | Delta | Omicron | ||
| United States of America | ||||||
| AstraZeneca-Vaxzevria/SII-Covishield vaccine | 2nd | |||||
| Janssen-Ad26.COV 2.S vaccine | 1st | 79 (77–80) (43) | 78 (73–82) (43) | |||
| Moderna-mRNA-1273 vaccine | 2nd | 98.4 (96.9–99.1) (44) | 95.5 (90.9–97.8) (44) | 66.7 (58.9–73.0) (45) | 13.9 (10.5–17.1) (46) | |
| Pfizer BioNTech-Comirnaty vaccine | 2nd | 66.5 (58.3–73.1) (48) | 68.9 (61.9–74.7) (45) | 25 (20–30) (49) | ||
| Sinovac-CoronaVac vaccine | ||||||
| Canada | ||||||
| AstraZeneca-Vaxzevria/SII-Covishield vaccine | 2nd | 74 (29–90) (50) | §100 (no CI provided) (51) | 90 (61–98) (50) | 70 (66–73) (50) | |
| Janssen-Ad26.COV 2.S vaccine | ||||||
| Moderna-mRNA-1273 vaccine | 2nd | 95 (85–98) (50) | §100 (no CI provided) (51) | 95 (85–99) (50) | 92 (91–93) (50) | |
| Pfizer BioNTech-Comirnaty vaccine | 2nd | 96 (93–98) (50) | §81 (−38–97) (51) | 93 (89–95) (50) | 91 (91–92) (50) | |
| Sinovac-CoronaVac vaccine | ||||||
| Spain | ||||||
| AstraZeneca-Vaxzevria/SII-Covishield vaccine | 2nd | 38 (−42–73) (41) | 55 (39–67) (41) | |||
| Janssen-Ad26.COV 2.S vaccine | 1st | 77 (27–93) (41) | 42 (18–59) (41) | |||
| Moderna-mRNA-1273 vaccine | 2nd | 86 (56–95) (41) | 77 (64–85) (41) | |||
| Pfizer BioNTech-Comirnaty vaccine | 2nd | 71 (61–78) (41) | 67 (59–74) (41) | |||
| Sinovac-CoronaVac vaccine | ||||||
| United Kingdom | ||||||
| AstraZeneca-Vaxzevria/SII-Covishield vaccine | 2nd | 73 (66–78) (42) | 78.9 (66.6–86.7) (27) | 11.4 (−18.8–34.6) (27) | ||
| Janssen-Ad26.COV 2.S vaccine | ||||||
| Moderna-mRNA-1273 vaccine | 2nd | 87.8 (79.8–92.7) (27) | 23.7 (4.4–39.4) (27) | |||
| Pfizer BioNTech-Comirnaty vaccine | 2nd | 92 (90–93) (42) | 83.5 (78.6–87.3) (27) | 26.0 (−18.8–34.6) (27) | ||
| Sinovac-CoronaVac vaccine | ||||||
| Qatar | ||||||
| AstraZeneca-Vaxzevria/SII-Covishield vaccine | ||||||
| Janssen-Ad26.COV 2.S vaccine | ||||||
| Moderna-mRNA-1273 vaccine | 2nd | 100 (91.8–100) (52) | 96.4 (91.9–98.7) (52) | 73.1 (67.5–77.8) (53) | ⊙52 (45.8–57.4) (54) | |
| Pfizer BioNTech-Comirnaty vaccine | 2nd | 87 (82–91) (55) | 72 (66–77) (55) | 51.9 (47.0–56.4) (53) | ⊙55.5 (51.8–59) (54) | |
| Sinovac-CoronaVac vaccine | ||||||
| Brazil | ||||||
| AstraZeneca-Vaxzevria/SII-Covishield vaccine | 2nd | 88.1 (82.8–91.7) (56) | 59 (33.1–74.8) (57) | |||
| Janssen-Ad26.COV 2.S vaccine | ||||||
| Moderna-mRNA-1273 vaccine | ||||||
| Pfizer BioNTech-Comirnaty vaccine | ||||||
| Sinovac-CoronaVac vaccine | 2nd | 46.8 (38.7–53.8) (47) | #55 (54.3–55.7) (58) | |||
| Czech Republic | ||||||
| AstraZeneca-Vaxzevria/SII-Covishield vaccine | ||||||
| Janssen-Ad26.COV 2.S vaccine | 60 (57–63) (59) | 47 (45–49) (59) | ||||
| Moderna-mRNA-1273 vaccine | 2nd | 71 (65–76) (59) | 48 (44–52) (59) | |||
| Pfizer BioNTech-Comirnaty vaccine | 2nd | 96.2 (91.6–98.7) (60) | 65 (<0–96.6) (60) | 49 (48–50) (59) | ||
| Sinovac-CoronaVac vaccine | ||||||
*VE refers to vaccine effectiveness.
#The VE of Sinovac-CoronaVac vaccine is assessed against symptomatic infection in Brazil.
§The VE of vaccine is assessed against symptomatic infection ≥7 days after the 2nd dose.
⊙The VE of vaccine is assessed against symptomatic infection among individuals who infected previously after ≥14 days after 2nd dose.